Core Viewpoint - The board meeting of Tehai International (09658.HK) is scheduled for March 31, 2026, to consider and approve the unaudited financial performance for the three months ending December 31, 2025, the annual performance for the same period, and any proposed final dividend distribution [1] Financial Performance - The meeting will address the unaudited financial results for the fourth quarter ending December 31, 2025 [1] - The annual performance for the year ending December 31, 2025, will also be reviewed [1] Dividend Consideration - The board will consider the proposal for the distribution of a final dividend, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事會會議日期 特海国际控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈，董事會會議將於2026年3月31日（星期二）舉行，藉 以（其中包括）考慮及批准(i)本集團截至2025年12月31日止三個月的未經審核財 務業績（「第四季度業績」）及其發佈；(ii)本集團截至2025年12月31日止年度業績 （「年度業績」）及其發佈；及(iii)建議派發末期股息（如有）。 本集團將於同日於香港聯合交易所有限公司（「聯交所」）交易時段結束後於聯交所 網站(www.hkexnews.hk)公佈第四季度業績及年度業績。 SUPER HI INTERNATIONAL HOLDING LTD. 特海国际控股有限公司 （於開曼群島註冊成立的有限公司） （香港交易所股份代號：9658；納斯達克股票代碼：HDL） 主席 電話會議將會以英文及中文進行網上直播。參與者可透過以下鏈接觀 ...

Group 1 - The core viewpoint of the article is that Tehai International (09658.HK) has received a BBB rating in the latest ESG assessment by Huazheng Index, maintaining the same rating as the previous period [1] - In the latest ESG rating, Tehai International ranks 16th among 30 listed companies in the hotel, restaurant, and leisure industry in Hong Kong, down from 15th in the previous assessment [1] - The detailed scores for Tehai International are as follows: E score of 70.13 (B rating, 19th in the industry), S score of 81.82 (BBB rating, 16th in the industry), and G score of 84.72 (BBB rating, 13th in the industry) [1] Group 2 - Huazheng Index is a professional company engaged in index and index investment services, authorized to compile indices for the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Hong Kong Stock Exchange [2] - ESG stands for Environmental, Social, and Governance, which measures the sustainability of a company's development from these three perspectives [2]

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector's performance compared to the overall market [5][10]. Core Insights - The report highlights significant developments in the pharmaceutical sector, including a licensing agreement between China National Pharmaceutical Group (Sinopharm) and Sanofi for the JAK/ROCK inhibitor, and the approval of a new indication for Innovent Biologics' BTK inhibitor in China [1][2]. - Performance forecasts for companies such as Crystal Holding and He Yu indicate substantial revenue growth, with Crystal Holding expected to achieve at least 780 million RMB in revenue for 2025, representing a year-on-year increase of approximately 193% [6][7]. Summary by Sections 1. Overseas Pharmaceuticals - Sinopharm and Sanofi have entered into an exclusive licensing agreement for the global development, production, and commercialization of the JAK/ROCK inhibitor, with potential milestone payments totaling up to 1.395 billion USD [2][7]. - Innovent Biologics' BTK inhibitor, Jiepalit (Pirtobrutinib), has received NMPA approval for a new indication in adult patients with chronic lymphocytic leukemia (CLL) who have previously undergone systemic treatment [2][7]. - Roche's BTK inhibitor Fenebrutinib has successfully met primary endpoints in a Phase III trial for relapsing multiple sclerosis, potentially becoming the first effective oral treatment for both relapsing and primary progressive forms of the disease [3][8]. 2. Performance Updates - Crystal Holding anticipates a revenue of no less than 780 million RMB in 2025, with a net profit of at least 100 million RMB, marking a turnaround from losses [6][7]. - He Yu expects to achieve 612 million RMB in revenue for 2025, reflecting a 21% year-on-year growth, with net profit projected at 55 million RMB, a 95% increase [6][7]. 3. Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and others [10]. - It also highlights the importance of monitoring clinical progress in key pipelines for companies transitioning towards innovation [10].

Core Viewpoint - The independent listing platform of Haidilao Group, Tehai International, forecasts a significant increase in net profit for 2025 primarily driven by foreign exchange gains, while restaurant operations are expected to decline due to a proactive discount strategy [1] Financial Performance - Tehai International anticipates revenue of no less than $840 million for 2025, with net profit attributable to shareholders expected to be at least $34 million, compared to $780 million in revenue and $21.8 million in net profit for the same period in 2024 [1] - The forecasted net profit growth is largely attributed to foreign exchange gains, with expected net foreign exchange gains rising from a loss of $19.7 million in 2024 to a gain of $14 million in 2025 due to currency fluctuations [1] Restaurant Operations - The operating profit margin in the restaurant segment is expected to decline as the company implements a proactive discount strategy to maintain table turnover and customer traffic amid intense competition [1] - Despite the discount strategy, restaurant traffic and turnover rates have shown growth, with total customer traffic reaching 8.1 million in Q3 2025, a year-on-year increase of 9.5%, and the average turnover rate improving from 3.8 times per day in Q3 2024 to 3.9 times in Q3 2025 [2] Cost Pressures - Tehai International is facing ongoing cost pressures, particularly in labor, with employee costs increasing by 9.7%, 12.1%, and 7.9% year-on-year in the first three quarters of 2025 [2] Competitive Landscape - The international Chinese restaurant market is becoming increasingly fragmented, with notable competitors accelerating their overseas expansion, marking a shift from a "hotpot monopoly" to a "multi-category competition" phase [2]

公司名稱: 特海国际控股有限公司 呈交日期: 2026年3月5日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 截至月份: 2026年2月28日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09658 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 致：香港交易及結算所有限 ...

Core Viewpoint - The company expects to achieve revenue of no less than $840 million for the year ending December 31, 2025, compared to $778 million for the year ending December 31, 2024, indicating a positive growth trajectory in revenue [1] - The company anticipates a profit attributable to owners of no less than $34 million for the year ending December 31, 2025, up from approximately $21.8 million for the year ending December 31, 2024, reflecting a significant increase in profitability [1] Revenue and Profit Forecast - Projected revenue for the year ending December 31, 2025, is $840 million, representing an increase from $778 million in 2024, which is a growth of approximately 8% [1] - Expected profit attributable to owners for the year ending December 31, 2025, is $34 million, which is an increase of about 55% from $21.8 million in 2024 [1] Factors Influencing Profit Growth - The increase in profit is primarily attributed to net foreign exchange gains expected to be around $14 million for the year ending December 31, 2025, compared to a net foreign exchange loss of $19.7 million for the year ending December 31, 2024 [1] - The change in foreign exchange results is mainly due to unrealized foreign exchange gains arising from currency revaluation of monetary items, which are denominated in a non-reporting currency (USD) [1] Operational Challenges - Despite the growth in profit, the operating profit margin at the restaurant level has slightly decreased compared to the previous year [1] - This decline in margin is attributed to the company's proactive strategy of offering discounts and increasing investments in customers and employees, leading to anticipated increases in employee costs, raw material costs, and other operating expenses [1]

Core Viewpoint - The company, 特海国际 (09658.HK), expects significant revenue and profit growth for the fiscal year ending December 31, 2025, compared to the previous year [1] Financial Performance - The company anticipates revenue of no less than $840 million for the fiscal year ending December 31, 2025, an increase from $778 million for the fiscal year ending December 31, 2024 [1] - The expected profit attributable to the owners of the company is projected to be no less than $34 million for the fiscal year ending December 31, 2025, up from approximately $21.8 million for the fiscal year ending December 31, 2024 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SUPER HI INTERNATIONAL HOLDING LTD. 特海国际控股有限公司 （於開曼群島註冊成立的有限公司） （香港交易所股份代號：9658；納斯達克股票代碼：HDL） 盈利預告 本公告由特海国际控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例 第571章證券及期貨條例第XIVA部之內幕消息條文（定義見上市規則）的規定作 出。 2 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，基於對 本集團截至2025年12月31日止年度的未經審核綜合管理賬目所作出的初步審閱， 以及對董事會目前可獲得的最新資料所作出的評估，本集團預計，(i)於截至2025 年12月31日止年度，將錄得不低於840.0百萬美元的收入，而於截至2024年12月 31日止年度的收入為778.3百萬美元 ...

Core Insights - The report highlights changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies. Group 1: Recent Increases in Holdings - VITASOY INT'L (00345) saw an increase of 0.09%, bringing its latest holding percentage to 3.75% [1] - 恒生科技ETF (03032) increased by 0.04%, with a current holding of 18.49% [1] - 永升服务 (01995) experienced a rise of 0.01%, now holding 4.57% [1] - 南方东西精选 (03441) had the largest increase over five days at 18.46%, reaching 41.03% [4] - 喜相逢集团 (02473) increased by 10.04%, with a holding of 45.14% [4] - 兆易创新 (03986) rose by 4.95%, now at 6.65% [4] Group 2: Recent Decreases in Holdings - 南方恒生科技 (03033) experienced the largest decrease of -0.14%, with a current holding of 68.87% [2] - 医渡科技 (02158) decreased by -0.03%, now at 22.59% [2] - 盈富基金 (02800) saw a reduction of -0.02%, with a holding of 3.49% [2] - 山东墨龙 (00568) had a five-day decrease of -1.30%, now at 53.56% [5] - 亿华通 (02402) decreased by -1.00%, with a holding of 27.49% [5] - 国富氢能 (02582) saw a reduction of -0.90%, now at 20.14% [5] Group 3: Long-term Trends in Holdings - Over a 20-day period, 喜相逢集团 (02473) had the highest increase of 42.45%, reaching 45.14% [6] - 南方东西精选 (03441) increased by 27.31%, now at 41.03% [6] - 钧达股份 (02865) rose by 15.74%, with a holding of 64.80% [6] - 天齐锂业 (09696) experienced a significant decrease of -6.48%, now at 31.50% [6] - 金风科技 (02208) decreased by -5.88%, with a holding of 42.49% [6]